
Ji-Ye Yin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2991009/publications.pdf Version: 2024-02-01



ILVE VIN

#	Article	IF	CITATIONS
1	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. International Journal of Biological Sciences, 2022, 18, 1844-1851.	6.4	34
2	Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment. Molecular Therapy - Nucleic Acids, 2022, 28, 464-476.	5.1	11
3	Association of variations in the Fanconi anemia complementation group and prognosis in Non–small cell lung cancer patients with Platinum-based chemotherapy. Gene, 2022, 825, 146398.	2.2	2
4	Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Molecular Cancer, 2022, 21, 98.	19.2	36
5	Abstract LB548: Genomic analysis of antineoplastic drug-related genetic variations based on large-scale population sequencing. Cancer Research, 2022, 82, LB548-LB548.	0.9	0
6	Targeting translation regulators improves cancer therapy. Genomics, 2021, 113, 1247-1256.	2.9	12
7	COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19. International Journal of Biological Sciences, 2021, 17, 2080-2088.	6.4	6
8	Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. Acta Pharmacologica Sinica, 2021, 42, 1970-1980.	6.1	4
9	A Two-Stage Study Identifies Two Novel Polymorphisms in PRKAG2 Affecting Metformin Response in Chinese Type 2 Diabetes Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 745-755.	0.7	3
10	Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Frontiers in Immunology, 2021, 12, 685370.	4.8	32
11	Association between CASC16 rs4784227 polymorphism and breast cancer susceptibility. Medicine (United States), 2021, 100, e26215.	1.0	4
12	Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude. EPMA Journal, 2021, 12, 307-324.	6.1	11
13	The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair. Biochemical Pharmacology, 2021, 190, 114616.	4.4	7
14	Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy. Frontiers in Pharmacology, 2021, 12, 709528.	3.5	4
15	eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer. Pharmacological Research, 2021, 174, 105934.	7.1	11
16	Analytics of the clinical implementation of pharmacogenomics testing in 12Â758 individuals. Clinical and Translational Medicine, 2021, 11, e586.	4.0	5
17	LncRNA FOXD1â€AS1 acts as a potential oncogenic biomarker in glioma. CNS Neuroscience and Therapeutics, 2020, 26, 66-75.	3.9	34
18	A New Way to Discover IRESs in Pathology or Stress Conditions? Harnessing Latest Highâ€Throughput Technologies. BioEssays, 2020, 42, 1900180.	2.5	0

#	Article	IF	CITATIONS
19	MASS SPECTROMETRYâ€BASED PERSONALIZED DRUG THERAPY. Mass Spectrometry Reviews, 2020, 39, 523-552	2.5.4	31
20	Remdesivir and COVID-19. Lancet, The, 2020, 396, 953-954.	13.7	21
21	Genetic Variants in DNA Mismatch Repair Pathway predict prognosis of Lung Cancer patients with receiving Platinum-Based Chemotherapy. Journal of Cancer, 2020, 11, 5281-5288.	2.5	4
22	Epidemiological and clinical features of pediatric COVID-19. BMC Medicine, 2020, 18, 250.	5.5	88
23	The Association Between Heat-Shock Protein Polymorphisms and Prognosis in Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Pharmacology, 2020, 11, 1029.	3.5	4
24	Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC. OncoTargets and Therapy, 2020, Volume 13, 6485-6496.	2.0	7
25	Breaking the Intracellular Redox Balance with Diselenium Nanoparticles for Maximizing Chemotherapy Efficacy on Patient-Derived Xenograft Models. ACS Nano, 2020, 14, 16984-16996.	14.6	105
26	Association of variations in platinum resistance-related genes and prognosis in lung cancer patients. Journal of Cancer, 2020, 11, 4343-4351.	2.5	3
27	<p>A Hereditable Mutation of MSH2 Gene Associated with Lynch Syndrome in a Five Generation Chinese Family</p> . Cancer Management and Research, 2020, Volume 12, 1469-1482.	1.9	4
28	Pharmacogenomics for the efficacy of platinum-based chemotherapy: Old drugs, new integrated perspective. Biomedicine and Pharmacotherapy, 2020, 126, 110057.	5.6	4
29	The role of single strand break repair pathways in cellular responses to camptothecin induced DNA damage. Biomedicine and Pharmacotherapy, 2020, 125, 109875.	5.6	29
30	The role of CSDE1 in translational reprogramming and human diseases. Cell Communication and Signaling, 2020, 18, 14.	6.5	43
31	Abstract 1289: CSDE1 mediated translation reprogramming under stress. , 2020, , .		0
32	The IDO genetic polymorphisms and postpartum depressive symptoms: an association study in Chinese parturients who underwent cesarean section. Archives of Women's Mental Health, 2019, 22, 339-348.	2.6	16
33	Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway. Frontiers in Oncology, 2019, 9, 508.	2.8	72
34	Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. Brain Research, 2019, 1719, 30-39.	2.2	14
35	The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor. Journal of Cancer, 2019, 10, 1622-1632.	2.5	55
36	Precision dosing of warfarin: open questions and strategies. Pharmacogenomics Journal, 2019, 19, 219-229.	2.0	17

#	Article	IF	CITATIONS
37	CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. Journal of Cancer, 2019, 10, 6374-6383.	2.5	25
38	Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy. IUBMB Life, 2018, 70, 183-191.	3.4	64
39	Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer. Gynecologic Oncology, 2018, 149, 341-349.	1.4	12
40	elF3a: A new anticancer drug target in the elF family. Cancer Letters, 2018, 412, 81-87.	7.2	50
41	Possible Strategies to Make Warfarin Dosing Algorithm Prediction More Accurately in Patients With Extreme Dose. Clinical Pharmacology and Therapeutics, 2018, 103, 184-184.	4.7	6
42	Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. Journal of Thoracic Disease, 2018, 10, 3329-3340.	1.4	12
43	Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. Current Pharmacogenomics and Personalized Medicine, 2018, 16, 108-117.	0.2	0
44	Gene expression and single nucleotide polymorphism of ATP7B are associated with platinum-based chemotherapy response in non-small cell lung cancer patients. Journal of Cancer, 2018, 9, 3532-3539.	2.5	18
45	Resistin facilitates metastasis of lung adenocarcinoma through the <scp>TLR</scp> 4/Src/ <scp>EGFR</scp> / <scp>PI</scp> 3K/ <scp>NF</scp> â€PB pathway. Cancer Science, 2018, 109, 2391-2400.	3.9	33
46	Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population. European Journal of Clinical Pharmacology, 2018, 74, 1021-1028.	1.9	8
47	Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy, 2018, Volume 11, 529-538.	2.0	13
48	Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer. Scientific Data, 2018, 5, 180284.	5.3	9
49	ATP7B rs9535826 is associated with gastrointestinal toxicity of platinum-based chemotherapy in nonsmall cell lung cancer patients. Journal of Cancer Research and Therapeutics, 2018, 14, 881.	0.9	9
50	MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Scientific Reports, 2017, 7, 40384.	3.3	73
51	Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients. Chinese Journal of Cancer, 2017, 36, 12.	4.9	15
52	Effects of gene polymorphisms in the endoplasmic reticulum stress pathway on clinical outcomes of chemoradiotherapy in Chinese patients with nasopharyngeal carcinoma. Acta Pharmacologica Sinica, 2017, 38, 571-580.	6.1	10
53	Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Medical Oncology, 2017, 34, 48.	2.5	51
54	Association between well-characterized lung cancer IncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer. Acta Pharmacologica Sinica, 2017, 38, 581-590.	6.1	56

#	Article	IF	CITATIONS
55	Genetic variants of the kynurenine-3-monooxygenase and postpartum depressive symptoms after cesarean section in Chinese women. Journal of Affective Disorders, 2017, 215, 94-101.	4.1	24
56	Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Scientific Reports, 2017, 7, 8072.	3.3	55
57	Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. Scientific Reports, 2017, 7, 5593.	3.3	28
58	Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Scientific Reports, 2017, 7, 5082.	3.3	28
59	eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response. Methods in Molecular Biology, 2017, 1507, 113-127.	0.9	6
60	Ageâ€related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinumâ€based chemotherapy. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 21-29.	1.9	18
61	Genome-wide DNA methylation profiling reveals novel epigenetic signatures in squamous cell lung cancer. BMC Genomics, 2017, 18, 901.	2.8	63
62	Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells. Oncology Reports, 2017, 37, 1196-1202.	2.6	33
63	Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget, 2017, 8, 97476-97489.	1.8	33
64	Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget, 2017, 8, 21281-21289.	1.8	49
65	The molecular classification of astrocytic tumors. Oncotarget, 2017, 8, 96340-96350.	1.8	9
66	Abstract 1407: Translational regulation of RPA2 via IRES by UNR and eIF3a. , 2017, , .		0
67	PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma. International Journal of Molecular Sciences, 2016, 17, 1808.	4.1	49
68	COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget, 2016, 7, 70494-70503.	1.8	62
69	Evaluation of <i>DNMT3A</i> genetic polymorphisms as outcome predictors in AML patients. Oncotarget, 2016, 7, 60555-60574.	1.8	18
70	The Impacts of <i>SLC22A1</i> rs594709 and <i>SLC47A1</i> rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. International Journal of Endocrinology, 2016, 2016, 1-7.	1.5	46
71	Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2016, 17, 839.	4.1	49
72	MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. Oncotarget, 2016, 7, 40038-40046.	1.8	47

#	Article	IF	CITATIONS
73	Polymorphisms of <i>ABAT</i> , <i>SCN2A</i> and <i>ALDH5A1</i> may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics, 2016, 17, 2007-2014.	1.3	29
74	Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. Cancer Letters, 2016, 377, 65-73.	7.2	23
75	Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Chinese lournal of Cancer, 2016, 35, 85.	4.9	38
76	Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics, 2016, 17, 1365-1378.	1.3	33
77	Establishing Prediction Model of Antiepileptic Drugs Response using Data Mining Approach. CNS Neuroscience and Therapeutics, 2016, 22, 860-862.	3.9	0
78	A critical overview of long non-coding RNA in glioma etiology 2016: an update. Tumor Biology, 2016, 37, 14403-14413.	1.8	17
79	Association of well-characterized lung cancer IncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumor Biology, 2016, 37, 8349-8358.	1.8	149
80	Circulating resistin levels and obesity-related cancer risk: A meta-analysis. Oncotarget, 2016, 7, 57694-57704.	1.8	33
81	Prognostic and predictive values of CDK1 and MAD2L1 in lung adenocarcinoma. Oncotarget, 2016, 7, 85235-85243.	1.8	83
82	Common variants of ATP1A3 but not ATP1A2 are associated with Chinese genetic generalized epilepsies. Journal of the Neurological Sciences, 2015, 354, 56-62.	0.6	12
83	Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response. Clinical Lung Cancer, 2015, 16, 298-304.e2.	2.6	24
84	Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients. Acta Pharmacologica Sinica, 2015, 36, 375-384.	6.1	21
85	Genome-scale long noncoding RNA expression pattern in squamous cell lung cancer. Scientific Reports, 2015, 5, 11671.	3.3	29
86	Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics, 2015, 16, 583-590.	1.3	49
87	<i>IL-1B</i> rs1143623 and <i>EEF1A1P11-RPL7P9</i> rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients. Pharmacogenomics, 2015, 16, 1621-1629.	1.3	6
88	Effect of CYP2C9–VKORC1 interaction on warfarin stable dosage and its predictive algorithm. Journal of Clinical Pharmacology, 2015, 55, 251-257.	2.0	19
89	elF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation. Oncotarget, 2015, 6, 25441-25451.	1.8	39
90	The Association of Transporter Genes Polymorphisms and Lung Cancer Chemotherapy Response. PLoS ONE, 2014, 9, e91967.	2.5	31

#	Article	IF	CITATIONS
91	Huperzine A Ameliorates Cognitive Deficits in Streptozotocin-Induced Diabetic Rats. International Journal of Molecular Sciences, 2014, 15, 7667-7683.	4.1	81
92	PRRT2 Mutations Are Related to Febrile Seizures in Epileptic Patients. International Journal of Molecular Sciences, 2014, 15, 23408-23417.	4.1	16
93	JAZF1 regulates visfatin expression in adipocytes via PPARα and PPARβ/δ signaling. Metabolism: Clinical and Experimental, 2014, 63, 1012-1021.	3.4	19
94	Association of <i><scp>HMGB</scp>1</i> and <i><scp>HMGB</scp>2</i> genetic polymorphisms with lung cancer chemotherapy response. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 408-415.	1.9	26
95	The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumor Biology, 2014, 35, 8259-8265.	1.8	18
96	Association of ABCB1 Polymorphisms With the Efficacy of Ondansetron in Chemotherapy-induced Nausea and Vomiting. Clinical Therapeutics, 2014, 36, 1242-1252.e2.	2.5	43
97	The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers. PLoS ONE, 2014, 9, e96008.	2.5	26
98	Two Novel Functional Single Nucleotide Polymorphisms ofADRB3Are Associated With Type 2 Diabetes in the Chinese Population. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1272-E1277.	3.6	15
99	Translational regulation of RPA2 via internal ribosomal entry site and by eIF3a. Carcinogenesis, 2013, 34, 1224-1231.	2.8	30
100	Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients. PLoS ONE, 2012, 7, e38150.	2.5	47
101	<i>ABCC2</i> Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients. CNS Neuroscience and Therapeutics, 2012, 18, 647-651.	3.9	76
102	<i>ABCC1</i> polymorphism Arg723Gln (2168Gâ€f>â€fA) is associated with lung cancer susceptibility in a Chinese population. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 632-637.	1.9	13
103	Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. Bioscience Reports, 2011, 31, 1-15.	2.4	46
104	Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair. Clinical Cancer Research, 2011, 17, 4600-4609.	7.0	74
105	Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenetics and Genomics, 2009, 19, 206-216.	1.5	60
106	Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer. Frontiers in Pharmacology, 0, 13, .	3.5	2